P19963 · ALL1_OLEEU
- ProteinMajor pollen allergen Ole e 1
- StatusUniProtKB reviewed (Swiss-Prot)
- Organism
- Amino acids145 (go to sequence)
- Protein existenceEvidence at protein level
- Annotation score5/5
Function
function
May be involved in recognition between pollen-stigma and pollen tube-style cells.
Miscellaneous
Replacement of several other amino acids by Ala has little or no effect on IgG binding.
GO annotations
all annotations | all molecular function | nucleotide binding | molecular_function | nucleic acid binding | dna binding | chromatin binding | dna-binding transcription factor activity | rna binding | cytoskeletal motor activity | catalytic activity | nuclease activity | signaling receptor binding | structural molecule activity | transporter activity | binding | protein binding | translation factor activity, rna binding | lipid binding | kinase activity | transferase activity | hydrolase activity | oxygen binding | enzyme regulator activity | carbohydrate binding | signaling receptor activity | translation regulator activity | transcription regulator activity | other molecular function | all biological process | carbohydrate metabolic process | generation of precursor metabolites and energy | nucleobase-containing compound metabolic process | dna metabolic process | translation | lipid metabolic process | transport | response to stress | cell cycle | cell communication | signal transduction | cell-cell signaling | multicellular organism development | circadian rhythm | biological_process | metabolic process | catabolic process | biosynthetic process | response to light stimulus | response to external stimulus | tropism | response to biotic stimulus | response to abiotic stimulus | response to endogenous stimulus | embryo development | post-embryonic development | fruit ripening | abscission | pollination | flower development | cellular process | programmed cell death | photosynthesis | cellular component organization | cell growth | protein metabolic process | cellular homeostasis | secondary metabolic process | reproductive process | cell differentiation | protein modification process | growth | epigenetic regulation of gene expression | response to chemical | anatomical structure development | regulation of molecular function | other biological process | all cellular component | cellular_component | extracellular region | cell wall | intracellular anatomical structure | nucleus | nuclear envelope | nucleoplasm | nucleolus | cytoplasm | mitochondrion | lysosome | endosome | vacuole | peroxisome | endoplasmic reticulum | golgi apparatus | cytosol | ribosome | cytoskeleton | plasma membrane | chloroplast | plastid | thylakoid | membrane | external encapsulating structure | other cellular component | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aspect | Term | |
---|---|---|
Cellular Component | endoplasmic reticulum | |
Cellular Component | extracellular space |
Protein family/group databases
Names & Taxonomy
Protein names
- Recommended nameMajor pollen allergen Ole e 1
- Alternative names
- Allergen nameOle e 1
Organism names
- Organism
- Strains
- Taxonomic lineageEukaryota > Viridiplantae > Streptophyta > Embryophyta > Tracheophyta > Spermatophyta > Magnoliopsida > eudicotyledons > Gunneridae > Pentapetalae > asterids > lamiids > Lamiales > Oleaceae > Oleeae > Olea
Accessions
- Primary accessionP19963
- Secondary accessions
Subcellular Location
Phenotypes & Variants
Allergenic properties
Causes an allergic reaction in human. Major allergen from olive pollen. Important in Mediterranean countries.
Features
Showing features for natural variant, mutagenesis.
Type | ID | Position(s) | Description | |||
---|---|---|---|---|---|---|
Natural variant | 3 | in Ole e 1.0102, Ole e 1.0103 and Ole e 1.0105 | ||||
Sequence: I → V | ||||||
Natural variant | 8 | in Ole e I.4 | ||||
Sequence: V → I | ||||||
Mutagenesis | 8 | 90% loss of IgG binding. | ||||
Sequence: V → A | ||||||
Mutagenesis | 9 | Loss of IgG binding. | ||||
Sequence: S → A | ||||||
Mutagenesis | 10 | Loss of IgG binding. | ||||
Sequence: Q → A | ||||||
Mutagenesis | 11 | Loss of IgG binding. | ||||
Sequence: F → A | ||||||
Natural variant | 12 | in Ole e I.4 | ||||
Sequence: H → Y | ||||||
Natural variant | 13 | in strain: cv. Zard; variant 2. In Ole e I.4 | ||||
Sequence: I → V | ||||||
Natural variant | 14 | in strain: cv. Bella de Espana; variants 1 and 2, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine and cv. Picual; variant 1 | ||||
Sequence: Q → I | ||||||
Natural variant | 15 | in strain: cv. Picual; variant 1 | ||||
Sequence: G → L | ||||||
Natural variant | 15 | in strain: cv. Arbequina; variants 1 and 2 and cv. Bella de Espana; variant 3 | ||||
Sequence: G → Q | ||||||
Natural variant | 15 | in strain: cv. Bella de Espana; variants 1 and 2, cv. Menara; variants 1 and 2 and cv. Picholine marocaine | ||||
Sequence: G → R | ||||||
Natural variant | 15 | in strain: cv. Picual; variant 3 | ||||
Sequence: G → S | ||||||
Natural variant | 15 | in strain: cv. Loaime and cv. Picual; variant 2 | ||||
Sequence: G → W | ||||||
Natural variant | 16 | in strain: cv. Arbequina; variant 1 | ||||
Sequence: Q → A | ||||||
Natural variant | 16 | in strain: cv. Arbequina; variant 2, cv. Bella de Espana; variant 3 and cv. Picual; variant 3 | ||||
Sequence: Q → D | ||||||
Natural variant | 16 | in strain: cv. Acebuche | ||||
Sequence: Q → R | ||||||
Natural variant | 16 | in strain: cv. Bella de Espana; variants 1 and 2, cv. Loaime, cv. Menara; variants 1 and 2, cv. Picholine marocaine and cv. Picual; variants 1 and 2 | ||||
Sequence: Q → T | ||||||
Natural variant | 17 | in strain: cv. Rowghani; variant 3 and cv. Zard; variant 2 | ||||
Sequence: V → I | ||||||
Natural variant | 17 | in strain: cv. Arbequina; variant 2, cv. Bella de Espana; variant 3, cv. Hojiblanca and cv. Picual; variant 3 | ||||
Sequence: V → S | ||||||
Natural variant | 17 | in strain: cv. Acebuche | ||||
Sequence: V → T | ||||||
Natural variant | 18 | in strain: cv. Bella de Espana; variant 1 | ||||
Sequence: Y → F | ||||||
Natural variant | 18 | in strain: cv. Menara; variant 2 | ||||
Sequence: Y → H | ||||||
Natural variant | 18 | in strain: cv. Bella de Espana; variant 2 and cv. Picual; variant 2 | ||||
Sequence: Y → S | ||||||
Natural variant | 18 | in strain: cv. Acebuche | ||||
Sequence: Y → V | ||||||
Natural variant | 19 | in strain: cv. Bella de Espana; variant 2 | ||||
Sequence: C → Q | ||||||
Natural variant | 19 | in strain: cv. Arbequina; variant 2 and cv. Bella de Espana; variant 1 | ||||
Sequence: C → R | ||||||
Natural variant | 19 | in strain: cv. Bella de Espana; variant 3 | ||||
Sequence: C → S | ||||||
Natural variant | 19 | in strain: cv. Acebuche | ||||
Sequence: C → T | ||||||
Natural variant | 20 | in strain: cv. Acebuche and cv. Bella de Espana; variant 3 | ||||
Sequence: D → G | ||||||
Natural variant | 20 | in strain: cv. Bella de Espana; variant 1 | ||||
Sequence: D → V | ||||||
Natural variant | 21 | in strain: cv. Bella de Espana; variant 3 | ||||
Sequence: T → H | ||||||
Natural variant | 21 | in strain: cv. Acebuche | ||||
Sequence: T → Y | ||||||
Natural variant | 23 | in strain: cv. Bella de Espana; variant 2 | ||||
Sequence: R → C | ||||||
Natural variant | 23 | |||||
Sequence: R → P | ||||||
Natural variant | 24 | in strain: cv. Rowghani; variant 3. In Ole e 1.0105 | ||||
Sequence: A → S | ||||||
Natural variant | 24 | in Ole e I.4 | ||||
Sequence: A → T | ||||||
Natural variant | 25 | in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variants 3 and 4. In Ole e 1.0105, Ole e I.3 and Ole e I.4 | ||||
Sequence: G → R | ||||||
Mutagenesis | 26 | 70% loss of IgG binding. | ||||
Sequence: F → A | ||||||
Natural variant | 28 | in strain: cv. Zard; variant 2; 50% loss of IgG binding | ||||
Sequence: T → A | ||||||
Mutagenesis | 29 | Loss of IgG binding. | ||||
Sequence: E → A | ||||||
Natural variant | 30 | in Ole e I.4 | ||||
Sequence: L → F | ||||||
Mutagenesis | 30 | 50% loss of IgG binding. | ||||
Sequence: L → A | ||||||
Mutagenesis | 32 | Loss of IgG binding. | ||||
Sequence: E → A | ||||||
Mutagenesis | 33 | Loss of IgG binding. | ||||
Sequence: F → A | ||||||
Mutagenesis | 34 | 50% loss of IgG binding. | ||||
Sequence: I → A | ||||||
Natural variant | 35 | in strain: cv. Zard; variant 2 | ||||
Sequence: P → L | ||||||
Natural variant | 38 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Zard; variant 2. In Ole e I.4 | ||||
Sequence: S → G | ||||||
Natural variant | 39 | in strain: cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1 and 2, cv. Rowghani; variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0102, Ole e 1.0103, Ole e 1.0105, Ole e I.3 and Ole e I.4 | ||||
Sequence: L → V | ||||||
Natural variant | 44 | in strain: cv. Rowghani; variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0105 | ||||
Sequence: K → R | ||||||
Natural variant | 45 | in strain: cv. Zard; variant 1 and cv. Rowghani; variants 2 and 3. In Ole e 1.0105 | ||||
Sequence: D → E | ||||||
Natural variant | 46 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Rowghani; variant 4. In Ole e I.3 and Ole e I.4 | ||||
Sequence: K → G | ||||||
Natural variant | 46 | |||||
Sequence: K → I | ||||||
Natural variant | 46 | in strain: cv. Arbequina; variants 1 and 2 | ||||
Sequence: K → R | ||||||
Natural variant | 46 | in strain: cv. Zard; variant 2 | ||||
Sequence: K → S | ||||||
Natural variant | 47 | in strain: cv. Rowghani; variant 2 and cv. Zard; variants 1 and 2 | ||||
Sequence: E → K | ||||||
Natural variant | 48 | in strain: cv. Zard; variant 2 | ||||
Sequence: N → K | ||||||
Mutagenesis | 49 | 50% loss of IgG binding. | ||||
Sequence: G → A | ||||||
Natural variant | 50 | in Ole e I.4 | ||||
Sequence: D → K | ||||||
Natural variant | 50 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca and cv. Zard; variant 2 | ||||
Sequence: D → N | ||||||
Natural variant | 50 | in strain: cv. Rowghani; variant 4. In Ole e I.3 | ||||
Sequence: D → S | ||||||
Mutagenesis | 50 | 60% loss of IgG binding. | ||||
Sequence: D → A | ||||||
Natural variant | 51 | in strain: cv. Arbequina; variants 1 and 2, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1 and 2, cv. Rowghani, variants 2, 3 and 4 and cv. Zard; variants 1 and 2. In Ole e 1.0105, Ole e I.3 and Ole e I.4 | ||||
Sequence: V → I | ||||||
Mutagenesis | 51 | 50% loss of IgG binding. | ||||
Sequence: V → A | ||||||
Mutagenesis | 55 | Loss of IgG binding. | ||||
Sequence: E → A | ||||||
Natural variant | 56 | in strain: cv. Rowghani; variant 3. In Ole e 1.0102, 1.0103 and 1.0105 | ||||
Sequence: V → I | ||||||
Mutagenesis | 56 | Loss of IgG binding. | ||||
Sequence: V → A | ||||||
Mutagenesis | 57 | Loss of IgG binding. | ||||
Sequence: G → A | ||||||
Natural variant | 58 | in strain: cv. Rowghani; variant 4 | ||||
Sequence: Y → S | ||||||
Mutagenesis | 58 | Loss of IgG binding. | ||||
Sequence: Y → A | ||||||
Mutagenesis | 59 | Loss of IgG binding. | ||||
Sequence: T → A | ||||||
Mutagenesis | 60 | 60% loss of IgG binding. | ||||
Sequence: R → A | ||||||
Mutagenesis | 65 | 70% loss of IgG binding. | ||||
Sequence: Y → A | ||||||
Mutagenesis | 67 | 50% loss of IgG binding. | ||||
Sequence: M → A | ||||||
Natural variant | 69 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4 | ||||
Sequence: V → I | ||||||
Mutagenesis | 70 | Loss of IgG binding. | ||||
Sequence: E → A | ||||||
Natural variant | 75 | in strain: cv. Rowghani; variant 4. In Ole e I.3 | ||||
Sequence: N → D | ||||||
Natural variant | 80 | in strain: cv. Zard; variant 2 | ||||
Sequence: I → V | ||||||
Natural variant | 81 | in strain: cv. Zard; variant 2 | ||||
Sequence: T → N | ||||||
Natural variant | 82 | in strain: cv. Zard; variant 2 | ||||
Sequence: L → S | ||||||
Natural variant | 83 | in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Zard; variant 2. In Ole e I.4 | ||||
Sequence: I → L | ||||||
Natural variant | 86 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4 | ||||
Sequence: G → S | ||||||
Natural variant | 87 | |||||
Sequence: R → S | ||||||
Natural variant | 91 | in strain: cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Loaime, cv. Picual; variants 1 and 2, cv. Rowghani; variants 3 and 4 and cv. Zard; variant 2. In Ole e 1.0105, Ole e I.3 and Ole e I.4 | ||||
Sequence: N → D | ||||||
Natural variant | 95 | in strain: cv. Rowghani; variant 3 and cv. Zard; variant 2. In Ole e 1.0105 | ||||
Sequence: T → I | ||||||
Natural variant | 95 | in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3 | ||||
Sequence: T → V | ||||||
Natural variant | 99 | in strain: cv. Acebuche, cv. Arbequina; variants 1 and 2, cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Picual; variant 3, cv. Rowghani; variants 1 and 4 and cv. Zard; variant 2. In Ole e I.2, Ole e I.3 and Ole e I.4 | ||||
Sequence: A → V | ||||||
Natural variant | 100 | in strain: cv. Zard; variant 2 | ||||
Sequence: K → R | ||||||
Natural variant | 103 | in Ole e I.4 | ||||
Sequence: L → V | ||||||
Natural variant | 104 | in strain: cv. Zard; variant 2 | ||||
Sequence: K → R | ||||||
Natural variant | 106 | in strain: cv. Acebuche, cv. Arbequina; variant 1 and 2, cv. Hojiblanca, cv. Loaime, cv. Lucio, cv. Menara; variants 1 and 2, cv. Picholine marocaine, cv. Picual; variants 1, 2 and 3, cv. Rowghani; variants 1, 2 and 3 and cv. Zard; variant 1. In Ole e 1.0102, Ole e 1.0103, Ole e 1.0105, Ole e I.2 and Ole e I.4 | ||||
Sequence: K → I | ||||||
Natural variant | 106 | in strain: cv. Zard; variant 2 | ||||
Sequence: K → L | ||||||
Natural variant | 106 | in strain: cv. Bella de Espana; variants 1, 2 and 3 and cv. Rowghani; variant 4. In Ole e I.3 | ||||
Sequence: K → M | ||||||
Mutagenesis | 107 | Loss of IgG binding. | ||||
Sequence: L → A | ||||||
Natural variant | 108 | in Ole e 1.0103 | ||||
Sequence: N → S | ||||||
Mutagenesis | 108 | Loss of IgG binding. | ||||
Sequence: N → A | ||||||
Mutagenesis | 109 | Loss of IgG binding. | ||||
Sequence: T → A | ||||||
Mutagenesis | 110 | Loss of IgG binding. | ||||
Sequence: V → A | ||||||
Natural variant | 111 | |||||
Sequence: N → D | ||||||
Mutagenesis | 112 | Loss of IgG binding. | ||||
Sequence: G → A | ||||||
Natural variant | 115 | in strain: cv. Zard; variant 2 | ||||
Sequence: R → C | ||||||
Natural variant | 117 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Hojiblanca, cv. Rowghani; variant 2 and cv. Zard; variants 1 and 2. In Ole e I.3 and Ole e I.4 | ||||
Sequence: V → I | ||||||
Natural variant | 118 | in strain: cv. Zard; variant 2 | ||||
Sequence: N → K | ||||||
Mutagenesis | 119 | 70% loss of IgG binding. | ||||
Sequence: P → A | ||||||
Mutagenesis | 120 | Loss of IgG binding. | ||||
Sequence: L → A | ||||||
Natural variant | 121 | in Ole e 1.0102 | ||||
Sequence: G → R | ||||||
Natural variant | 123 | in strain: cv. Zard; variant 1 and cv. Rowghani; variant 2. In Ole e 1.0102 and Ole e 1.0103 | ||||
Sequence: F → Y | ||||||
Mutagenesis | 123 | Loss of IgG binding. | ||||
Sequence: F → A | ||||||
Natural variant | 125 | in strain: cv. Zard; variant 2 | ||||
Sequence: K → N | ||||||
Mutagenesis | 125 | 80% loss of IgG binding. | ||||
Sequence: K → A | ||||||
Natural variant | 126 | in strain: cv. Zard; variant 2 | ||||
Sequence: E → K | ||||||
Natural variant | 132 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4 | ||||
Sequence: A → P | ||||||
Mutagenesis | 133 | 50% loss of IgG binding and 40% loss if IgE binding. | ||||
Sequence: Q → A | ||||||
Mutagenesis | 134 | 30% loss of IgG binding and 50% loss if IgE binding. | ||||
Sequence: V → A | ||||||
Natural variant | 135 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2. In Ole e I.3 and Ole e I.4 | ||||
Sequence: Y → F | ||||||
Mutagenesis | 135 | No loss of IgG binding and 40% loss if IgE binding. | ||||
Sequence: Y → A | ||||||
Mutagenesis | 136 | 40% loss of IgG binding and 60% loss if IgE binding. | ||||
Sequence: N → A | ||||||
Mutagenesis | 136-145 | Decreased IgE binding. | ||||
Sequence: Missing | ||||||
Mutagenesis | 137 | 20% loss of IgG binding and 80% loss if IgE binding. | ||||
Sequence: K → A | ||||||
Mutagenesis | 138 | 70% loss of IgG binding and 90% loss if IgE binding. | ||||
Sequence: L → A | ||||||
Natural variant | 139 | in strain: cv. Rowghani; variant 2 | ||||
Sequence: G → D | ||||||
Mutagenesis | 139 | 30% loss of IgG binding and 90% loss if IgE binding. | ||||
Sequence: G → A | ||||||
Mutagenesis | 140 | 50% loss of IgG binding and 50% loss if IgE binding. | ||||
Sequence: M → A | ||||||
Mutagenesis | 141 | 90% loss of IgG binding and 95% loss if IgE binding. | ||||
Sequence: Y → A | ||||||
Mutagenesis | 141-145 | Decreased IgE binding. | ||||
Sequence: Missing | ||||||
Mutagenesis | 142 | 20% loss of IgG binding and 95% loss if IgE binding. | ||||
Sequence: P → A | ||||||
Natural variant | 144 | in strain: cv. Bella de Espana; variants 1, 2 and 3, cv. Rowghani; variant 4 and cv. Zard; variant 2 | ||||
Sequence: N → D | ||||||
Natural variant | 144 | in strain: cv. Picual; variant 3 | ||||
Sequence: N → T | ||||||
Natural variant | 145 | in strain: cv. Acebuche | ||||
Sequence: M → HGMSR | ||||||
Natural variant | 145 | in strain: cv. Zard; variant 2 | ||||
Sequence: M → L | ||||||
Natural variant | 145 | in strain: cv. Picual; variant 3 | ||||
Sequence: M → WNVTI |
Variants
We now provide the "Disease & Variants" viewer in its own tab.
The viewer provides 88 variants from UniProt as well as other sources including ClinVar and dbSNP.
Keywords
- Disease
Protein family/group databases
PTM/Processing
Features
Showing features for chain, disulfide bond, glycosylation.
Type | ID | Position(s) | Description | |||
---|---|---|---|---|---|---|
Chain | PRO_0000215113 | 1-145 | Major pollen allergen Ole e 1 | |||
Sequence: EDIPQPPVSQFHIQGQVYCDTCRAGFITELSEFIPGASLRLQCKDKENGDVTFTEVGYTRAEGLYSMLVERDHKNEFCEITLISSGRKDCNEIPTEGWAKPSLKFKLNTVNGTTRTVNPLGFFKKEALPKCAQVYNKLGMYPPNM | ||||||
Disulfide bond | 19↔90 | |||||
Sequence: CDTCRAGFITELSEFIPGASLRLQCKDKENGDVTFTEVGYTRAEGLYSMLVERDHKNEFCEITLISSGRKDC | ||||||
Disulfide bond | 22↔131 | |||||
Sequence: CRAGFITELSEFIPGASLRLQCKDKENGDVTFTEVGYTRAEGLYSMLVERDHKNEFCEITLISSGRKDCNEIPTEGWAKPSLKFKLNTVNGTTRTVNPLGFFKKEALPKC | ||||||
Disulfide bond | 43↔78 | |||||
Sequence: CKDKENGDVTFTEVGYTRAEGLYSMLVERDHKNEFC | ||||||
Glycosylation | 111 | N-linked (GlcNAc...) (complex) asparagine; alternate | ||||
Sequence: N | ||||||
Glycosylation | 111 | N-linked (GlcNAc...) (high mannose) asparagine; alternate | ||||
Sequence: N |
Post-translational modification
N-glycosylated; contains high mannose (Man7-GlcNAc) and partially fucosylated complex glycans (GlcNAc-Man3-Xyl-GlcNAc). Complex glycans may contribute to the antigenicity. Exists both in a glycosylated and in a non-glycosylated form. Ole e 1 and Ole e 1.0103 are the only non-glycosylated isoallergens.
A second potential glycosylation site exists at position 50 in cv. Bella de Espana and cv. Hojiblanca.
Keywords
- PTM
PTM databases
Expression
Tissue specificity
Expressed in tapetum and pollen grains. Not detected in petals, roots or leaves.
Developmental stage
Expressed at late stages of pollen development. Up-regulated during pollen germination and pollen tube growth.
Structure
Family & Domains
Domain
Regions 91-102 and 109-130 are immunodominant T-cell epitopes. Mutations in the C-terminus (135-145) reduce allergenic activity but do not change the ability to stimulate allergen-specific T-cells.
Sequence similarities
Belongs to the Ole e I family.
Family and domain databases
Sequence
- Sequence statusComplete
- Length145
- Mass (Da)16,330
- Last updated1993-10-01 v2
- Checksum3F11F04E01C12C84
Sequence caution
Polymorphism
Several isoforms of the allergen exist due to polymorphism.
Keywords
- Technical term
Sequence databases
Nucleotide Sequence | Protein Sequence | Molecule Type | Status | |
---|---|---|---|---|
Y12426 EMBL· GenBank· DDBJ | CAA73036.1 EMBL· GenBank· DDBJ | mRNA | Different initiation | |
Y12427 EMBL· GenBank· DDBJ | CAA73037.1 EMBL· GenBank· DDBJ | mRNA | Different initiation | |
Y12428 EMBL· GenBank· DDBJ | CAA73038.1 EMBL· GenBank· DDBJ | mRNA | Different initiation | |
AF500908 EMBL· GenBank· DDBJ | AAQ07442.1 EMBL· GenBank· DDBJ | mRNA | ||
AF515277 EMBL· GenBank· DDBJ | AAQ08186.1 EMBL· GenBank· DDBJ | mRNA | ||
AF515278 EMBL· GenBank· DDBJ | AAQ08187.1 EMBL· GenBank· DDBJ | mRNA | ||
AF515279 EMBL· GenBank· DDBJ | AAQ08188.1 EMBL· GenBank· DDBJ | mRNA | ||
AF515280 EMBL· GenBank· DDBJ | AAQ08189.1 EMBL· GenBank· DDBJ | mRNA | ||
AF515281 EMBL· GenBank· DDBJ | AAQ08190.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532753 EMBL· GenBank· DDBJ | AAQ10267.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532754 EMBL· GenBank· DDBJ | AAQ10268.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532755 EMBL· GenBank· DDBJ | AAQ10269.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532756 EMBL· GenBank· DDBJ | AAQ10270.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532757 EMBL· GenBank· DDBJ | AAQ10271.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532758 EMBL· GenBank· DDBJ | AAQ10272.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532759 EMBL· GenBank· DDBJ | AAQ10273.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532760 EMBL· GenBank· DDBJ | AAQ10274.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532761 EMBL· GenBank· DDBJ | AAQ10275.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532762 EMBL· GenBank· DDBJ | AAQ10276.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532763 EMBL· GenBank· DDBJ | AAQ10277.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532764 EMBL· GenBank· DDBJ | AAQ10278.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532765 EMBL· GenBank· DDBJ | AAQ10279.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532766 EMBL· GenBank· DDBJ | AAQ10280.1 EMBL· GenBank· DDBJ | mRNA | ||
AF532767 EMBL· GenBank· DDBJ | AAQ10281.1 EMBL· GenBank· DDBJ | mRNA | ||
AY137467 EMBL· GenBank· DDBJ | AAN18042.1 EMBL· GenBank· DDBJ | mRNA | ||
AY137468 EMBL· GenBank· DDBJ | AAN18043.1 EMBL· GenBank· DDBJ | mRNA | ||
AY137469 EMBL· GenBank· DDBJ | AAN18044.1 EMBL· GenBank· DDBJ | mRNA | ||
AY159880 EMBL· GenBank· DDBJ | AAO22132.1 EMBL· GenBank· DDBJ | Genomic DNA | ||
AY159881 EMBL· GenBank· DDBJ | AAO22133.1 EMBL· GenBank· DDBJ | Genomic DNA | ||
EF541386 EMBL· GenBank· DDBJ | ABP58632.1 EMBL· GenBank· DDBJ | mRNA | ||
EF541387 EMBL· GenBank· DDBJ | ABP58633.1 EMBL· GenBank· DDBJ | mRNA | ||
EF541388 EMBL· GenBank· DDBJ | ABP58634.1 EMBL· GenBank· DDBJ | mRNA | ||
EF541389 EMBL· GenBank· DDBJ | ABP58635.1 EMBL· GenBank· DDBJ | mRNA | ||
EF541390 EMBL· GenBank· DDBJ | ABP58636.1 EMBL· GenBank· DDBJ | mRNA | ||
EF541391 EMBL· GenBank· DDBJ | ABP58637.1 EMBL· GenBank· DDBJ | mRNA | ||
S75766 EMBL· GenBank· DDBJ | AAB32652.2 EMBL· GenBank· DDBJ | mRNA |